165 related articles for article (PubMed ID: 37109594)
1. Comparing the Impact of COVID-19 on Vaccinated and Unvaccinated Patients Affected by Myasthenia Gravis.
Scarsi E; Massucco S; Ferraro PM; Cella A; Grisanti SG; Assini A; Beronio A; Della Cava F; Gemelli C; Bandini F; Serrati C; Del Sette M; Schenone A; Benedetti L; Prada V; Grandis M
Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109594
[TBL] [Abstract][Full Text] [Related]
2. Impact of COVID-19 Infection and Its Association With Previous Vaccination in Patients With Myasthenia Gravis in Korea: A Multicenter Retrospective Study.
Han HJ; Kim SW; Kim H; So J; Lee EJ; Lim YM; Lee JH; Lee MA; Kim BJ; Baek SH; Lee HS; Sohn E; Kim S; Park JS; Kang M; Park HJ; Yoon BA; Kim JK; Seok HY; Kim S; Min JH; Chung YH; Cho JH; Kim JE; Oh SI; Shin HY
J Korean Med Sci; 2024 May; 39(18):e150. PubMed ID: 38742290
[TBL] [Abstract][Full Text] [Related]
3. The impact of SARS-CoV-2 immunization on COVID-19 disease course in people with myasthenia gravis.
Bakirtzis C; Boziki MK; Karakasi MV; Moysiadis T; Grigoriadis N
Muscle Nerve; 2023 May; 67(5):412-416. PubMed ID: 36814101
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series.
Ruan Z; Tang Y; Li C; Sun C; Zhu Y; Li Z; Chang T
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696220
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting the intention of COVID-19 vaccination in Korean patients with myasthenia gravis: A survey-based study.
Kim S; Jeong SH; Shin HY; Kim SW
Front Neurol; 2022; 13():847873. PubMed ID: 35989937
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 pandemic year in a sample of Polish myasthenia gravis patients: an observational study.
Rzepiński Ł; Zawadka-Kunikowska M
Neurol Neurochir Pol; 2022; 56(1):61-67. PubMed ID: 34346049
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis.
Peric S; Rankovic M; Bozovic I; Radosavljevic V; Marjanovic I; Basta I; Lavrnic D
Acta Neurol Belg; 2023 Apr; 123(2):529-536. PubMed ID: 36279094
[TBL] [Abstract][Full Text] [Related]
8. Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis.
Gamez J; Gamez A; Carmona F
Muscle Nerve; 2022 Nov; 66(5):612-617. PubMed ID: 36029224
[TBL] [Abstract][Full Text] [Related]
9. Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.
Lupica A; Di Stefano V; Iacono S; Pignolo A; Quartana M; Gagliardo A; Fierro B; Brighina F
Neurol Int; 2022 Apr; 14(2):406-416. PubMed ID: 35645352
[TBL] [Abstract][Full Text] [Related]
10. BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
Doron A; Piura Y; Vigiser I; Kolb H; Regev K; Nesher N; Karni A
J Neurol; 2022 Dec; 269(12):6193-6201. PubMed ID: 35907046
[TBL] [Abstract][Full Text] [Related]
11. Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis.
Solé G; Mathis S; Friedman D; Salort-Campana E; Tard C; Bouhour F; Magot A; Annane D; Clair B; Le Masson G; Soulages A; Duval F; Carla L; Violleau MH; Saulnier T; Segovia-Kueny S; Kern L; Antoine JC; Beaudonnet G; Audic F; Kremer L; Chanson JB; Nadaj-Pakleza A; Stojkovic T; Cintas P; Spinazzi M; Foubert-Samier A; Attarian S
Neurology; 2021 Apr; 96(16):e2109-e2120. PubMed ID: 33568541
[TBL] [Abstract][Full Text] [Related]
12. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
[TBL] [Abstract][Full Text] [Related]
13. Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population.
Butt AA; Yan P; Shaikh OS; Mayr FB; Omer SB
Clin Infect Dis; 2022 Aug; 75(1):e849-e856. PubMed ID: 34893812
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis.
Efe C; Taşçılar K; Gerussi A; Bolis F; Lammert C; Ebik B; Stättermayer AF; Cengiz M; Gökçe DT; Cristoferi L; Peralta M; Massoumi H; Montes P; Cerda E; Rigamonti C; Yapalı S; Adali G; Çalışkan AR; Balaban Y; Eren F; Eşkazan T; Barutçu S; Lytvyak E; Zazueta GM; Kayhan MA; Heurgue-Berlot A; De Martin E; Yavuz A; Bıyık M; Narro GC; Duman S; Hernandez N; Gatselis NK; Aguirre J; Idilman R; Silva M; Mendizabal M; Atay K; Güzelbulut F; Dhanasekaran R; Montano-Loza AJ; Dalekos GN; Ridruejo E; Invernizzi P; Wahlin S
J Autoimmun; 2022 Oct; 132():102906. PubMed ID: 36088883
[TBL] [Abstract][Full Text] [Related]
16. Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.
Stascheit F; Grittner U; Hoffmann S; Mergenthaler P; Schroeter M; Ruck T; Pawlitzki M; Blaes F; Kaiser J; Schara U; Della-Marina A; Thieme A; Hagenacker T; Jacobi C; Berger B; Urban PP; Knop KC; Schalke B; Lee DH; Kalischewski P; Wiendl H; Meisel A
J Neurol; 2023 Jan; 270(1):1-12. PubMed ID: 36166068
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 infection in myasthenia gravis: Clinical course and outcomes.
Thomas EV; Bou G; Barton S; Hutto S; Garcia-Santibanez R
Muscle Nerve; 2023 Aug; 68(2):171-175. PubMed ID: 37326164
[TBL] [Abstract][Full Text] [Related]
18. Severe acute respiratory syndrome coronavirus 2 vaccine breakthrough infections: A single metro-based testing network experience.
Strickler SS; Esper A; Wells L; Wood A; Frediani JK; Nehl E; Waggoner JJ; Rebolledo PA; Levy JM; Figueroa J; Ramachandra T; Lam W; Martin GS
Front Med (Lausanne); 2022; 9():1031083. PubMed ID: 36507539
[TBL] [Abstract][Full Text] [Related]
19. Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.
Li HY; Shao LY; Song M; Hu SM; Yue YX; Li HF
Front Immunol; 2022; 13():923017. PubMed ID: 35990671
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival.
Jakubíková M; Týblová M; Tesař A; Horáková M; Vlažná D; Ryšánková I; Nováková I; Dolečková K; Dušek P; Piťha J; Voháňka S; Bednařík J
Eur J Neurol; 2021 Oct; 28(10):3418-3425. PubMed ID: 34080271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
